Semaglutide

Mechanism

Long-acting GLP-1 receptor agonism.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Weight loss
• Glycemic control
• Cardiovascular-risk context

Figures

Every figure below is replotted by this site from values published in the cited paper's text or tables — the numbers are the study's, the drawing is ours, and the evidence rung on each image is the rung of its source.

How it is given

With food

Restricted on the oral route. label “Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces of water).” OZEMPIC/RYBELSUS FDA prescribing information, dosage & administration.

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

approximately 1 week (168 hours) (human, SC) — study. OZEMPIC FDA prescribing information, section 12.3.

Storage

Reconstituted: Solution (not lyophilized). Unopened: 2-8C. After first use: 56 days at 15-30C or 2-8C; do not freeze. — source. FDA label, Ozempic.

In sport (WADA 2026)

Not prohibited. Approved medicine, so S0 does not apply; not named in any prohibited class. Monitored since 2024. Monitoring is not prohibition and needs no TUE. the list

The half-life on file is 1 wk, measured subcutaneously. On the schedule this record states — weekly — each dose is still at 50% of its own peak when the next is given, so the doses overlap: the peaks build to 2.00× the first.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Reported adverse effects

• Nausea

  Very common (>10%)onset: First weeks; often improves with timereported reversible

• Vomiting

  Common (1-10%)onset: Dose escalation periodsreported reversible

• Diarrhea

  Common (1-10%)onset: First weeksreported reversible

• Constipation

  Common (1-10%)onset: Ongoingreported reversible

• Delayed gastric emptying

  Mechanism-linkedonset: Dose-dependentreported reversible

• Pancreatitis (rare but serious)

  Rare (<0.1%)onset: Any timereversibility not on file

• Gallbladder events including cholelithiasis

  Uncommononset: With rapid weight lossreversibility not on file

• Injection site reactions

  Common (1-10%)onset: Immediatereported reversible

Literature on file 5

• human RCT
  Once-Weekly Semaglutide in Adults with Overweight or Obesity (N Engl J Med 2021) graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
• human RCT
  Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme (Eur J Heart Fail 2025) graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
• human RCT
  Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (New England Journal of Medicine 2016, cited 5867x) graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
• human RCT
  Once-Weekly Semaglutide in Adults with Overweight or Obesity (New England Journal of Medicine 2021, cited 4574x) graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
• human RCT
  FDA approval NDA213051 graded on: an FDA approval (NDA213051), which requires adequate and well-controlled human investigations — “NDA213051”

What is circulated not evidence 5

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose common nothing on file either way

  Microdosing guides circulate a 0.05 mg weekly starting dose — half the labelled 0.25 mg start — escalating by 0.1 mg every 4 weeks.

  The initial dosage for semaglutide microdosing is typically 0.05 mg for the first 4 weeks.

  On the record Dosing on file is 0.1-2.4 mg weekly; no dose below the labelled 0.25 mg start has an RCT record, and 0.05 mg is below even the corpus floor.

  Source 1 · Source 2

• unverified community data timing occasional nothing on file either way

  Stretching the injection interval to every 10 or 14 days instead of weekly is circulated as an alternative low-dose method.

  every 10 or 14 days

  On the record The label schedule on file is weekly; no extended-interval record exists.

  Source 1

• unverified community data benefit common nothing on file either way

  Microdosing is claimed to preserve muscle mass and facial appearance, avoiding so-called 'Ozempic face'.

  preserving muscle mass and facial anatomy, reducing the risk of developing an Ozempic face

  On the record Benefits on file are weight loss, glycaemic control and cardiovascular-risk context; no muscle- or face-preservation record exists at any dose.

  Source 1

• unverified community data benefit common nothing on file either way

  Microdosing is claimed to lower gastrointestinal side-effect risk while still delivering appetite effects.

  help lower the risk of these gastrointestinal side effects

  On the record No record exists for efficacy or side-effect rates below 0.25 mg; the claim is untested at the doses circulated.

  Source 1

• unverified community data sourcing common nothing on file either way

  Cost saving is circulated as a motive: one pen or vial is said to last two to three times longer at microdoses.

  a single injection [can be used] twice or thrice longer than standard doses

  On the record Nothing on file; the corpus records doses and evidence, not per-pen economics.

  Source 1

Identity

PubChem CID 56843331 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 56843331, the identifier on this record.

Molecular weight

4114

Molecular formula

C187H291N45O59

CAS number

910463-68-2

PubChem CID

56843331

ChEMBL

CHEMBL2108724

InChI key

DLSWIYLPEUIQAV-CCUURXOWSA-N

Sequence

HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N

InChI

InChI=1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1

Classified as

GLP-1 Receptor Agonismmechanism

This is the most common mechanism on the site, and each downstream effect carries its own rung rather than inheriting the receptor's. The rubric at /evidence/rubric is what keeps them separate.

Glucose Homeostasispathway

The readings a record may cite cover different windows: a fasting glucose is one moment, HbA1c reflects roughly the previous three months, a continuous monitor's average is neither. Comparing across them is a common error.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Also called

• Semaglutide
• sema
• glp 1 s
• glp1 s
• glp 1 sg
• glp 1 s box of 10
• sema glp 1

Listed prices 212

What 83 shops we track listed for Semaglutide, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record